Curis (CRIS) News Today $3.29 +0.11 (+3.46%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period X4 Pharmaceuticals (NASDAQ:XFOR) versus Curis (NASDAQ:CRIS) Critical ComparisonJanuary 17, 2025 | americanbankingnews.comCuris Shares Gain on Results From Leukemia-Treatment StudyJanuary 2, 2025 | marketwatch.comCuris files to sell 2.4M shares of common stock for holdersDecember 24, 2024 | markets.businessinsider.comCuris stock plunges to 52-week low, hits $3.5 amid downturnDecember 13, 2024 | investing.comPromising Clinical Trial Results and Robust Financial Projections Drive Buy Rating for EmavusertibDecember 11, 2024 | markets.businessinsider.comCuris announces additional data from TakeAim leukemia studyDecember 10, 2024 | tipranks.comCuris Announces Additional Data from TakeAim Leukemia StudyDecember 10, 2024 | prnewswire.comCuris granted FDA orphan designation for emavusertibDecember 3, 2024 | tipranks.comCuris Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...November 16, 2024 | uk.finance.yahoo.comCuris Inc. Receives Buy Rating: Strong Financials and Promising Clinical Trial Progress Drive Growth PotentialNovember 16, 2024 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comCuris, Inc.: Curis Provides Third Quarter 2024 Business UpdateNovember 15, 2024 | finanznachrichten.deCuris Inc. Reports Positive Q3 2024 EarningsNovember 15, 2024 | markets.businessinsider.comCuris Provides Third Quarter 2024 Business UpdateNovember 14, 2024 | prnewswire.comExamining the Future: Curis's Earnings OutlookNovember 14, 2024 | benzinga.comCuris Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 13, 2024 | gurufocus.comCuris to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024November 7, 2024 | prnewswire.comCuris price target lowered to $20 from $26 at H.C. WainwrightNovember 1, 2024 | markets.businessinsider.comCuris Inc. Gains ‘Buy’ Rating Amid Financial Stability and Promising Clinical DevelopmentsNovember 1, 2024 | markets.businessinsider.comCuris sells 2.398M shares at $4.92 in registered direct offeringOctober 29, 2024 | markets.businessinsider.comCuris Announces $12.1 Million Registered Direct and Concurrent Private PlacementOctober 29, 2024 | prnewswire.comCuris Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...October 9, 2024 | finance.yahoo.comBuy Rating Affirmed for Curis on Emavusertib’s Promising Clinical Data and Market PotentialSeptember 28, 2024 | markets.businessinsider.comCuris Announces the 3rd Annual Symposium on IRAK4 in CancerSeptember 23, 2024 | prnewswire.comNBC 'reaches decision on Cris Collinsworth's Sunday Night Football future'September 22, 2024 | dailymail.co.ukCuris to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 17, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in SeptemberSeptember 4, 2024 | prnewswire.comTruist Financial Sticks to Its Buy Rating for Curis (CRIS)August 23, 2024 | markets.businessinsider.comAnalysts' Revenue Estimates For Curis, Inc. (NASDAQ:CRIS) Are Surging HigherAugust 7, 2024 | finance.yahoo.comTruist Financial Reaffirms Their Buy Rating on Curis (CRIS)August 5, 2024 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Call TranscriptAugust 5, 2024 | msn.comEarnings call: Curis reports advancements in cancer treatment studiesAugust 4, 2024 | investing.comEarnings Update: Curis, Inc. (NASDAQ:CRIS) Just Reported And Analysts Are Boosting Their EstimatesAugust 4, 2024 | finance.yahoo.comBuy Rating on Curis’s Stock Amid Anticipated Data Updates and Promising Drug EfficacyAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Curis on Strong Financials and Promising Emavusertib TrialsAugust 2, 2024 | markets.businessinsider.comCuris, Inc. (CRIS) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | seekingalpha.comCuris Inc Q2 Loss Decreases, But Misses EstimatesAugust 1, 2024 | markets.businessinsider.comCuris Provides Second Quarter 2024 Financial and Operating UpdateAugust 1, 2024 | prnewswire.comCuris IncJuly 25, 2024 | money.usnews.comCuris to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024July 25, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conference in JulyJuly 10, 2024 | prnewswire.comWill Curis' TakeAim Trials Hit The Mark? July 8, 2024 | rttnews.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 8, 2024 | prnewswire.comBuy Rating Affirmed for Curis’s Emavusertib Following Promising Leukemia Study ResultsMay 15, 2024 | markets.businessinsider.comCuris (NASDAQ:CRIS) Receives Buy Rating from Truist FinancialTruist Financial reaffirmed a "buy" rating and set a $26.00 target price on shares of Curis in a research note on Wednesday.May 15, 2024 | marketbeat.comCuris Announces Additional Data from TakeAim Leukemia StudyMay 14, 2024 | prnewswire.comCuris to Present Updated Data from the TakeAim Leukemia StudyMay 10, 2024 | prnewswire.comQ2 2024 Earnings Forecast for Curis, Inc. Issued By HC Wainwright (NASDAQ:CRIS)Curis, Inc. (NASDAQ:CRIS - Free Report) - Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for Curis in a research report issued on Wednesday, May 8th. HC Wainwright analyst E. White now anticipates that the biotechnology company will post earnings of ($2May 10, 2024 | marketbeat.comCuris Buy Rating Affirmed on Strong Earnings and Promising Emavusertib TrialsMay 8, 2024 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.com Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Media Mentions By Week CRIS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRIS News Sentiment▼-0.860.49▲Average Medical News Sentiment CRIS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRIS Articles This Week▼11▲CRIS Articles Average Week Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Achieve Life Sciences News Today Agenus News Today Regulus Therapeutics News Today Fortress Biotech News Today SAB Biotherapeutics News Today Bolt Biotherapeutics News Today Molecular Templates News Today Amgen News Today Gilead Sciences News Today Vertex Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRIS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRIS Stock Alerts